Early	JJ
growth	NN
response	NN
transcription	NN
factors	NNS
:	:
key	JJ
mediators	NNS
of	IN
fibrosis	NN
and	CC
novel	JJ
targets	NNS
for	IN
anti-fibrotic	JJ
therapy	NN
.	.

Fibrosis	NN
is	VBZ
a	DT
deregulated	VBN
and	CC
ultimately	RB
defective	JJ
form	NN
of	IN
tissue	NN
repair	NN
that	WDT
underlies	VBZ
a	DT
large	JJ
number	NN
of	IN
chronic	JJ
human	JJ
diseases	NNS
,	,
as	RB
well	RB
as	IN
obesity	NN
and	CC
aging	NN
.	.

The	DT
pathogenesis	NN
of	IN
fibrosis	NN
involves	VBZ
multiple	JJ
cell	NN
types	NNS
and	CC
extracellular	JJ
signals	NNS
,	,
of	IN
which	WDT
transforming	VBG
growth	NN
factor	NN
-	:
(	(
TGF	NN
-	:
)	)
is	VBZ
pre-eminent	JJ
.	.

The	DT
prevalence	NN
of	IN
fibrosis	NN
is	VBZ
rising	VBG
worldwide	RB
,	,
and	CC
to	TO
date	NN
no	DT
agents	NNS
has	VBZ
shown	VBN
clinical	JJ
efficacy	NN
in	IN
the	DT
attenuating	NN
or	CC
reversing	VBG
the	DT
process	NN
.	.

Recent	JJ
studies	NNS
implicate	VBP
the	DT
immediate-early	JJ
response	NN
transcription	NN
factor	NN
Egr-1	NN
in	IN
the	DT
pathogenesis	NN
of	IN
fibrosis	NN
.	.

Egr-1	NN
couples	NNS
acute	JJ
changes	NNS
in	IN
the	DT
cellular	JJ
environment	NN
to	TO
sustained	JJ
alterations	NNS
in	IN
gene	NN
expression	NN
,	,
and	CC
mediates	VBZ
a	DT
broad	JJ
spectrum	NN
of	IN
biological	JJ
responses	NNS
to	TO
injury	NN
and	CC
stress	NN
.	.

In	IN
contrast	NN
to	TO
other	JJ
ligand-activated	JJ
transcription	NN
factors	NNS
such	JJ
as	IN
NF-kB	NN
,	,
c-jun	NN
and	CC
Smad2/3	NN
that	WDT
undergo	VBP
post-translational	JJ
modification	NN
such	JJ
as	IN
phosphorylation	NN
and	CC
nuclear	JJ
translocation	NN
,	,
Egr-1	NN
activity	NN
is	VBZ
regulated	VBN
via	IN
its	PRP$
biosynthesis	NN
.	.

Aberrant	JJ
Egr-1	NN
expression	NN
or	CC
activity	NN
is	VBZ
implicated	VBN
in	IN
cancer	NN
,	,
inflammation	NN
,	,
atherosclerosis	NN
,	,
and	CC
ischemic	JJ
injury	NN
and	CC
recent	JJ
studies	NNS
now	RB
indicate	VBP
an	DT
important	JJ
role	NN
for	IN
Egr-1	NN
in	IN
TGF	NN
-	:
-	:
dependent	JJ
profibrotic	JJ
responses	NNS
.	.

Fibrosis	NN
in	IN
various	JJ
animal	NN
models	NNS
and	CC
human	JJ
diseases	NNS
such	JJ
as	IN
scleroderma	NN
(	(
SSc	NN
)	)
and	CC
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
accompanied	VBN
by	IN
aberrant	JJ
Egr-1	NN
expression	NN
.	.

Moreover	RB
Egr-1	NN
appears	VBZ
to	TO
be	VB
required	VBN
for	IN
physiologic	JJ
and	CC
pathological	JJ
connective	JJ
tissue	NN
remodeling	NN
,	,
and	CC
Egr-1-null	JJ
mice	NNS
are	VBP
protected	VBN
from	IN
fibrosis	NN
.	.

As	IN
a	DT
novel	JJ
profibrotic	JJ
mediator	NN
,	,
Egr-1	NN
thus	RB
appears	VBZ
to	TO
be	VB
a	DT
promising	JJ
potential	JJ
target	NN
for	IN
the	DT
development	NN
of	IN
anti-fibrotic	JJ
therapies	NNS
.	.

